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Abstract

EFFECT OF COMBINED ORAL CONTRACEPTIVES ON INSULIN CLEARANCE
IN LEAN AND OBESE PRE-MENOPAUSAL WOMEN

By
Vidya Moorthy, B.Pharm.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Pharmaceutical Sciences at Virginia Commonwealth University

Virginia Commonwealth University, 2011

Major Director: Dr. Kai I. Cheang, Pharm.D. M.S
Associate Professor, Department of Pharmacotherapy and Outcome Sciences

Introduction: Obese women are predisposed to greater risks of insulin resistance and
compensatory hyperinsulinemia. Likewise, African-Americans, appear to be inherently
insulin

resistant

and

hyperinsulinemic

even

after

controlling

for

obesity.

Hyperinsulinemia has been attributed to insulin resistance and a compensatory insulin
hyper-secretion by the pancreas, as well as decreased insulin clearance, notably in
obesity. Pharmacological agents that may worsen insulin resistance/hyperinsulinemia in
obese women is of clinical relevance. Previous data from our group suggested that
combined oral contraceptives (COCs) may worsen insulin sensitivity particularly in obese
viii

women, but limited information on insulin clearance is available in obese women or
African-American women.
Objective: The objective of the study is to evaluate and compare the effect of a COC
containing ethinyl estradiol and norgestimate on insulin clearance among lean and obese
pre-menopausal women and among African-American obese vs. non African-American
obese women.
Method: Plasma insulin clearance was calculated from plasma insulin concentrations,
following frequently sampled intravenous glucose tolerance test.

Changes in insulin

clearance, during six months of COC use were analyzed by repeated measures analysis.
Result: Six months of COC use showed no significant change in insulin clearance in all
women (p=0.3713). Furthermore, there were no divergent effects on insulin clearance
among lean (n=13) and obese (n=14) women (p=0.6703) and among African-American
obese (n=7) and non African-American obese (n=7) women (p=0.0957). Changes in
insulin clearance, following six months of COC administration was found to be positively
correlated with changes in insulin sensitivity (r=0.385, p=0.0099) and negatively
correlated with changes in acute insulin response to glucose (r=-0.432, p=0.0034).
Discussion: In the present study, COC administration did not show any differential effect
on insulin clearance in lean vs. obese women. Future studies evaluating the effects of
hormonal agents on insulin-glucose dynamics may focus on mechanisms of hormonemediated insulin resistance and compensatory hyperinsulinemia rather than insulin
clearance.

ix

1. INTRODUCTION
Obesity, defined as body mass index (BMI) ≥ 30 kg/m2 has assumed epidemic proportion, with
over 32% of the adult population in the United States found to be obese (1). Sixty percent of
adult women in particular are found to be overweight (BMI ≥ 25 kg/m2) (2).

Obesity raises the risk of type 2 diabetes mellitus, dyslipidemia, and coronary heart disease.
Interestingly, 80% of the subjects with type 2 diabetes mellitus are obese and insulin resistant
(3).

The major premise underpinning type 2 diabetes is insulin resistance (impaired insulin-mediated
glucose uptake). Obesity has a significant role to play in the pathophysiology of insulin
resistance (4) and consequent hyperinsulinemia (5). Obesity may accelerate insulin response by
increasing β cell induced insulin secretion and decreasing insulin clearance, especially in insulin
resistant individuals (6). Hyperinsulinemia is found to be a strong predictor for insulin resistance
syndrome, type 2 diabetes mellitus, hypertension, coronary artery disease, stroke and even cancer
(4;7;8). Thus, worsening of insulin resistance and consequent hyperinsulinemia in obese women
is of immense clinical relevance.

Combined Oral Contraceptives (COCs) are the leading form of contraception in the United
States (9) with over 11.6 million women receiving a prescription for it (10). Although COCs in
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general do not worsen glucose tolerance (11), most studies evaluating the effect of COC on
glucose metabolism have been performed in lean healthy women.

COC may also alter insulin clearance and lead to hyperinsulinemia. One study suggested the
possible role of progestin (norethindrone) in reducing insulin clearance, consequently leading to
hyperinsulinemia (12). These findings were replicated in another study, which demonstrated
significant decrease in insulin elimination during COC use containing norethindrone and
desogestrel (13). Both studies were conducted in healthy lean women.

Our research group has previously reported that insulin sensitivity is altered differentially
depending on obesity status (14). Specifically, insulin sensitivity worsened with COC more so in
obese women as compared with lean women. However, whether obesity status also affects
COC’s alteration of insulin clearance is unknown.

Hyperinsulinemia and abnormalities in hepatic insulin extraction has also been documented in
ethnic groups with severe insulin resistance (15). Pathophysiologically, several studies have
documented the greater prevalence of insulin resistance in the African-American population (16)
in comparison to Caucasians. Studies have shown that the African-American group is inherently
insulin resistant; displaying enhanced acute insulin response to glucose (AIRg) (17) and
decreased insulin clearance in comparison to their Caucasian counterparts (18-21). Thus, a
differential effect of COC on insulin clearance is also possible across ethnicity.
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Hence, in the present study, we compared the effect of a low-dose cyclic COC containing ethinyl
estradiol 35mcg and norgestimate 0.18/0.215/0.25 mg on insulin clearance in lean and obese premenopausal women, after six months of COC use. In addition, we also performed a pilot analysis
to evaluate the effect of insulin clearance in African-American obese women and non AfricanAmerican obese women. We also explored the relationship between changes in insulin clearance
and changes in glucose-insulin dynamics following six months of COC use.

3

Specific Aims
We hypothesize that exogenous administration of a low-dose COC is likely to decrease insulin
clearance, more so in obese as compared to lean pre-menopausal women, and more so in
African-American women as compared with Caucasian women. We tested our objective through
the following specific aims:
Specific Aim 1:
Test the effect of a low-dose COC (containing ethinyl estradiol and norgestimate) on insulin
clearance after six months of use in all pre-menopausal women.
Specific Aim 2:
Compare the effect of a low-dose COC (containing ethinyl estradiol and norgestimate) on insulin
clearance after six months of use in lean and obese pre-menopausal women.
Specific Aim 3:
Perform a preliminary analysis to determine the effect of a low-dose COC (containing ethinyl
estradiol and norgestimate) on insulin clearance after six months of use in African-American
obese and non African-American obese pre-menopausal women.
Specific Aim 4:
To explore the relationship between changes in insulin clearance and changes in glucose-insulin
dynamics, following six months of COC use.
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2. BACKGROUND
Obesity and Hyperinsulinemia
The prevalence of obesity has doubled from 15% to 30% in the past three decades (2). In the
United States, more than 60% of adult women are overweight (BMI ≥ 25 kg/m2). Obesity has
been associated with conventional cardiovascular risk factors along with increase in
inflammatory markers [high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor
necrosis factor-α (TNF-α)], non-esterified fatty acids (NEFA), and coronary artery endothelial
dysfunction (2). Obese women are pre-disposed to greater risks of type 2 diabetes mellitus and
other cardiovascular complications.

Obesity and insulin resistance/hyperinsulinemia are known risk factors for type 2 diabetes
mellitus, cardiovascular diseases and hypertension (22). Also, obesity has been associated with
insulin resistance and compensatory hyperinsulinemia (23).

A number of putative mechanisms that underlie the temporal relationship between obesity and
insulin resistance/hyperinsulinemia have been suggested. Some studies suggest that obesity
precedes the clinical expression of insulin resistance/hyperinsulinemia (22). It is hypothesized
that increase in body fat (esp. visceral fat) mobilizes the circulation of free fatty acids (FFAs) in
portal vein circulation, thereby reducing the hepatic insulin clearance, thus contributing to
peripheral hyperinsulinemia (24). Utilization of excess FFAs by muscles, at the expense of
glucose may contribute to insulin resistance in obesity (25). Similarly, increased levels of NEFA,
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as observed in obesity, also contributes to insulin resistance as a result of competition with
glucose for substrate oxidation (26). Increased NEFA levels results in increased intracellular
content of fatty acid metabolites like diacylglycerol (DAG), fatty acyl-coenzyme, and ceramide,
which results in phosphorylation of insulin receptor substrate 1 and 2 (IRS1 and IRS2), leading
to decreased activation of phosphatidyl inositol-3-OH kinase [PI(3)K]. Decreased signalling of
PI(3)K induces hepatic gluconeogenesis and insulin resistance (26). A post-receptor defect has
also been postulated with obesity. With increase in the adipose cell size, reduction in the insulin
effect on glucose oxidation has been reported owing to decrease in the number of insulin
receptors (24). Further, increased secretion of mediators of inflammation like IL-6, CRP, TNF-α
by adipose tissue in obesity have also been linked with insulin resistance (22;26;27). Also, levels
of adiponectin, an insulin-sensitizer, stimulating fatty acid oxidation is known to be lowered in
obesity (26).

Conversely, hyperinsulinemia may also contribute to obesity. Figure 1 shows an algorithm,
describing the role of hyperinsulinemia in obesity. It is hypothesized that hyperinsulinemia
interferes with leptin signal transduction in the hypothalamus, thereby promoting leptin
resistance (28). Thus, the ability of leptin to stimulate α-melanocyte stimulating hormone and
inhibit neuropeptide γ is hindered. This results in a decrease in resting energy expenditure (REE)
and increase in appetite, promoting weight gain. In addition, hyperinsulinemia prevents
dopamine reuptake at the nucleus accumbens, which promotes increased calorie intake (28).
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Figure 1: Role of hyperinsulinemia in obesity

Abbreviations: GLP-1- Glucagon like peptide 1; GIP- Gastric inhibitory polypeptide

Various factors contribute to hyperinsulinemia, including vagus nerve induced insulin hypersecretion, insulin resistance, and decreased insulin clearance (28). It is believed that
hyperinsulinemia, insulin resistance and glucose stimulated insulin release are intertwined
biologically (8). Hyperinsulinemia could result as a compensatory response to decreased insulin
sensitivity. β-cells adapt to a chronic state of insulin resistance by secreting more insulin in
response to a given plasma glucose levels (29). At the same time, hyperinsulinemia might itself
perpetuate insulin resistance. Continuous exposure to insulin causes a reduction in the insulin
receptor exposed on the cell surface, promoting internalization, followed by degradation (8).

Savage et al conducted a study to evaluate if hyperinsulinemia associated with obesity was a
result of reduced hepatic extraction or hyper-secretion of insulin by the pancreas. In a study
7

conducted in normoglycemic, 10 Pima Indians and 10 Caucasians with varying degrees of
obesity, the researchers found that the molar ratio of C-peptide to insulin was not significantly
correlated with varying degree of obesity (r=0.08) (30). However, insulin and C-peptide
concentrations were significantly correlated with degrees of obesity, with elevated levels of Cpeptide and insulin in obese subjects. These results indicate that hyperinsulinemia in obese
subjects is a result of pancreatic hyper-secretion. Additionally, obesity may also affect insulin
clearance. In a study by Meistas et al, total metabolic clearance of insulin was 33% lower in
obese subjects than non-obese subjects (31). Hyperinsulinemia has also been closely linked to
decreased hepatic insulin degradation in subjects with cirrhosis and liver dysfunction (32). These
results underscore the fact that decreased hepatic insulin extraction could be a possible reason for
hyperinsulinemia in obesity.

African-American Race and Hyperinsulinemia
Rising rates of obesity among African-Americans in comparison to Caucasians (33;34), along
with a confluence of lifestyle-environmental and genetic factors, may have contributed to the
greater prevalence of type 2 diabetes and concomitant cardiovascular complications in the
African-American population (16). African-American women in particular showed 2 fold greater
prevalence of type 2 diabetes in comparison to Caucasian women (35;36).

However, lifestyle factors alone do not explain the disproportionately increased insulin resistance
in African-Americans. Epidemiological studies have shown that African-Americans are
significantly more insulin resistant and hyperinsulinemic than their Caucasian counterparts, even
8

after adjusting for body fat (20;35-38). In the Bogalusa Heart Study of 377 children (5-17 years),
in comparison to Caucasian children, African-American children were found to have higher
insulin response during oral glucose tolerance test (OGTT) and greater insulin to glucose ratio,
suggestive of inherent insulin resistance (17). Hyperinsulinemia in African-Americans have been
explained by hyper-secretion of insulin, as a compensatory response to decreased insulin
sensitivity, and also by decreased insulin clearance (18-21;35;36;38), notably in obesity (36).
Both lean and obese African-American pre-menopausal women were found to have significantly
higher AIRg in comparison to their weight-matched Caucasian peers (36;37). In a study by Albu
et al, a 163% significant increase in AIRg was noted in healthy African-American premenopausal women when compared to Caucasian women (39). In another study, 14% lower
insulin clearance and 63% higher first phase insulin secretion than Caucasian adolescents,
accounted for hyperinsulinemia among African-American adolescents (38). One possible reason
for decreased insulin clearance could be because of lower liver mass among African-Americans
(20). In a study conducted in 22 healthy, pre-pubertal African-American and Caucasian children,
African-American children were found to have 15% lower insulin clearance when compared
with Caucasian children, even after adjusting for adiposity. Similarly, these results were
replicated even in African-American adults (15;36).
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Clinical Consequence of Hyperinsulinemia
Clinical consequence of insulin resistance and compensatory hyperinsulinemia are increasingly
appreciated for their role in type 2 diabetes mellitus and associated macro-vascular
complications.

Insulin resistance and consequent hyperinsulinemia precedes the clinical expression of type 2
diabetes mellitus. Subjects with diabetes are 2-4 times more likely to have heart disease (40).
Epidemiologic data have suggested that insulin resistance and consequent hyperinsulinemia is a
risk factor for cardiovascular disease. Compared to normoinsulinemic, non-obese subjects;
hyperinsulinemic, non-obese subjects with impaired glucose tolerance were associated with a
cluster of cardiovascular risk factors such as elevated triglycerides, low levels of high density
lipoprotein (HDL) and elevated systolic blood pressure (41). In the San Antonio Heart Study,
hyperinsulinemia predicted the development of type 2 diabetes, low levels of HDL, high
triglyceride levels, and hypertension over 8 years of follow-up (40;42). Additionally, in a metaanalysis of 12 prospective based studies, insulin was found to be a positive indicator of
cardiovascular disease, particularly in middle aged adults (40). The Quebec Cardiovascular
Study and the Insulin Resistance Atherosclerotic Study (IRAS) also provides a strong association
between insulin resistance/hyperinsulinemia and development of cardiovascular disease (40;42).
In the IRAS study, a significant association was reported between insulin resistance and intima
media thickness of the carotid artery.
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Hyperinsulinemia has the potential to raise or maintain the blood pressure by promoting renal
sodium absorption and stimulating the sympathetic nervous system (43). Also, the vasodilatatory
action of insulin, owing to endothelial nitric oxide release, is reduced in obese subjects (43).
Insulin resistance and consequent hyperinsulinemia is a strong predictor of coronary artery
disease (4). Insulin resistance results in increased release of FFA into the circulation (7). Flux of
FFA in the liver stimulates the secretion of very low density lipoprotein (VLDL), leading to
hypertriglyceridemia. VLDL stimulates the exchange of cholesteryl esters (CE) from HDL and
low density lipoprotein (LDL) for VLDL triglycerides (VLDL TG). Apolipoprotein A-I that
dissociates from TG-enriched HDL, reduces the availability of HDL for reverse cholesterol
transport. Also, TG-enriched LDL undergoes lipolysis to give rise to small, dense LDL.
Culmination of low levels of HDL and the presence of small, dense LDL contribute to
cardiovascular disease (7). Figure 2 provides a simplified model linking insulin resistance and
cardiovascular disease.
Figure 2: Model linking insulin resistance and cardiovascular disease

Hyperinsulinemia may also directly inhibit fibrinolysis in obese, insulin resistant individuals (7).
Visceral obesity is associated with increased levels of plasminogen activator inhibitor-I (PAI-I),
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which complexes with plasminogen and eliminates its fibrinolytic activity (4). Hypercoagulability and impaired fibrinolysis in insulin resistant individuals add to the pathological
basis for increased cardiovascular events (7).

Combined Oral Contraceptives and Glucose-Insulin Metabolism
COCs are the most common form of contraception, with over 100 million women using it
worldwide (10). In the US alone, 11.6 million women are COC users (10). In fact, 4 of the top
200 prescribed drugs in the US comprise of COCs.

Studies have substantiated the ability of COC to impair glucose tolerance within six months of
use (12;13;44-46). In one of the earlier studies, Doar et al studied the effects of COC use and
obesity on plasma glucose and pyruvate levels. In comparison to non-obese subjects, obese
subjects were found to have significantly higher blood glucose and pyruvate levels (47).
However, it was a cross-sectional study, providing little information on different indices of
glucose metabolism.

Exogenous estrogens may have different effects on carbohydrate metabolism based on doses
used (48). In comparison to higher doses, lower dose COC are known to produce fewer side
effects (49). Administration of exogenous low concentration (10X) of 17 β estradiol
(dose=0.326µg/day) in ovariectomized rats was found to up-regulate IRS-1, subsequently
increasing the insulin sensitivity in muscle and adipose tissue (50). However, high concentration
12

(100X) of 17 β estradiol (dose=0.326µg/day) was found to produce an opposite effect (50).
High-dose COC (ethinyl estradiol- EE >50 µg + progestin) use in particular resulted in the
development of impaired glucose tolerance in 15.4% of current COC users (n=354) versus 6.3%
of non-COC users (n=1732) (44). In women with diabetes mellitus, administration of high-dose
COC resulted in further worsening of glucose metabolism in 73% of the users (44). In women
with previous gestational diabetes, high-dose COC (0.08 mg mestranol) use resulted in the
development of impaired glucose tolerance in 2 of 12 subjects, along with deterioration in 4 of
12 subjects in a period of 2 weeks. Integrated insulin response to glucose, though delayed, was
also found to increase by 2 fold (51). Additionally, in a cross-sectional study conducted in
women on COC containing 0.1mg mestranol + 2mg norethindrone (high-dose) for a period of
9.5 years, 12 out of 31 subjects were found to have abnormal glucose tolerance (46). Marginally
reducing the dose and duration of COC use (sequential type COC containing 0.08mg mestranol +
2mg chlormadinone acetate for a period of 6.5 years) resulted in only 1 out of 31 women with
abnormal glucose tolerance (46). These results substantiate the deleterious effects of high-dose
COC on glucose metabolism. Thus, a transition from high-dose to low-dose COC use was made
in clinical practice. A recent Cochrane analysis suggested that low-dose COC (EE ≤ 35 µg) may
have limited effects on glucose metabolism in normal weight women (11). However, a few
studies have shown that even low-dose COC, with estrane (norethindrone) and gonane
(levonorgestrel, norgestrel) progestins, are associated with impaired glucose homeostasis
(44;45). In a study by Wynn, 210 women who initiated COC (EE 30 µg + levonorgestrel 150 µg)
were prospectively followed for a period of 3 years. At the end of 3 months, 13% of the subjects
were found to be glucose intolerant. While at 15th, 25th and 37th months, the number of glucose
intolerant subjects were found to increase to 10%, 20% and 30% respectively (46). Similarly, in
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a cross-sectional study, low-dose Lovral® (EE 30 µg + norgestrel) users also showed lowered
insulin sensitivity and glucose effectiveness (ability of glucose to promote its uptake at basal
insulin levels) in comparison to control users (never used or discontinued COC use in the past 24
months) (45). Hence, although the recent Cochrane analysis showed that low-dose COC use had
little effect on glucose metabolism in healthy lean women with no known risk of diabetes (11),
evidence exist that the risk is present. Importantly, we have limited information regarding obese
women (11).

Effect of low-dose COC on glucose metabolism also depends on the type of progestins.
Progestins have been shown to antagonize the effect of insulin on glucose metabolism in adipose
tissue and skeletal muscle, by bringing about a decrease in the target tissue insulin receptor
number and affinity (49). Gonane progestins (levonorgestrel, norgestrel) in particular may
elevate blood glucose and insulin levels (11;44). On the other hand, newer progestins such as
desogestrel and drospirenone were found to have a limited effect on carbohydrate metabolism,
when used for 1 year (44;52). COC’s progestin component’s effects on carbohydrate metabolism
has been attributed to their androgenic activity (46;48). Low androgenic hormonal contraceptives
(e.g. containing medroxy progesterone acetate) were associated with reduced risk of gestational
diabetes mellitus (Odds Ratio=0.84, 95% CI 0.58-1.22), in comparison to high androgenic
contraceptives like levonorgestrel (Odds Ratio=1.43, 95% CI 0.92-2.22) (53). In a study
comparing the effects of COC with the progestin drospirenone (17-α spirolactone derivative,
with anti-androgenic property) and desogestrel on glucose metabolism, no significant changes in
fasting glucose and insulin levels were observed at the end of cycle 6 and 13, in both the
treatment groups. The mean area under the curve-AUC (0-3 hr) for glucose moderately increased
14

by 28.7 mg/dL*h in the drospirenone group and by 22.2 mg/dL*h in the desogestrel group.
Modest increase in mean insulin levels was also observed. But none of these effects were
significant (52). Norgestimate, the proposed progestin in our study has little adverse effects on
carbohydrate metabolism. In a study by Burkman et al, no significant changes in fasting blood
glucose, insulin or glycosylated hemoglobin levels were observed at the end of 2 years of COC
use containing norgestimate (54).

Studies have also suggested that the progestin component may prolong insulin half life and
decrease insulin clearance (12;55;56). In a study evaluating the effect of COC (combined
formulations of 30-40 µg EE with triphasic regimen of levonorgestrel and monophasic regimen
of desogestrel and norethindrone) on glucose metabolism in healthy Caucasian women, the
researchers found that the desogestrel combination significantly decreased the insulin elimination
constant in comparison to non-COC users (13). The mean insulin half-life was found to be 5.06
minutes in non-COC users and 6.48 minutes in desogestrel combination users (13). Similar
effects have also been demonstrated by norethindrone-type preparations. Addition of
norethindrone 1mg to ethinyl estradiol was found to significantly decrease the rate constant for
insulin disappearance, when compared to ethinyl estradiol alone (9.97 ± 0.25%/min vs. 9.39 ±
0.22%/min, p <0.03) (12). These results suggest the possibility that the progestin component may
decrease insulin clearance, and thereby prolonging its circulation.
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Knowledge Gap
Previous studies have suggested that hyperinsulinemia could be a result of compensatory
increased secretion of insulin, due to insulin resistance or due to decreased insulin clearance,
notably in obesity (35;36;57). Our research group has previously conducted a study to determine
if there was a differential effect of COC on insulin sensitivity, depending on obesity status. The
study found divergent effects of COC on insulin sensitivity in lean vs. obese women, with obese
women displaying lowered insulin sensitivity (14). Six months of COC use worsened insulin
sensitivity in obese women, with no significant change in AIRg. If insulin sensitivity and AIRg
are related by a hyperbolic curve (58), then reduction in insulin sensitivity in obese subjects
would have been compensated by increased AIRg. However, in the aforementioned study by our
research group, no change in AIRg was observed with COC use. This postulated the possibility
of decreased insulin clearance, contributing to hyperinsulinemia, with COC use. Hence, the
objective of the study was to determine if insulin clearance is different in obese vs. lean premenopausal women after COC use.

Numerous studies have suggested that African-Americans have a greater degree of obesity and
are predisposed to insulin resistance/hyperinsulinemia and consequent type 2 diabetes mellitus
and cardiovascular complications, in comparison to their Caucasian counterparts (1820;35;36;38;39;59;60). Hence, we also tested the effect of COC on insulin clearance in AfricanAmerican obese vs. non African-American obese pre-menopausal women.
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Significance
Obese women are at a greater risk of insulin resistance and hyperinsulinemia (23;25-27).
Hyperinsulinemia has been associated with insulin resistance syndrome, hypertension, coronary
artery disease, and coagulation abnormalities (4). Hyperinsulinemia can result from insulin
resistance or decreased insulin clearance. Although COC’s effect on glucose metabolism and
insulin resistance in lean women are well known, data on obese women are sparse. This is a
critical knowledge gap, as obese women are already at a greater risk of insulin resistance and
hyperinsulinemia, and further worsening of this condition is of clinical relevance to these
women. The specific objective of this study is to evaluate the effect of a low-dose COC
(containing ethinyl estradiol and norgestimate) on insulin clearance in lean and obese premenopausal women. Furthermore, we tested if the difference in insulin clearance differed across
African-American obese and non African-American obese women, owing to greater prevalence
of obesity, insulin resistance/hyperinsulinemia in this population (34-36).

The proposed study is innovative because no study to date has prospectively compared the effect
of COC on insulin clearance in lean and obese pre-menopausal women. This contribution is
significant because it is a step towards a continuum of research in deciphering the processes
underlying impairment of glucose metabolism in obese women upon COC use.
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3. METHODS
Study Design
Our analysis of insulin clearance data was performed using data from a previously conducted
prospective single center trial, evaluating 13 lean (control group) and 14 obese pre-menopausal
women over a period of six months (14). In this study, we evaluated the effect of a low-dose
COC (containing ethinyl estradiol and norgestimate) on glucose-insulin homeostasis. Details of
this previous study are provided below along with the methodology used for the estimation of
insulin clearance in the current study.

Intervention
COC containing ethinyl estradiol 35 mcg and norgestimate 0.18/0.215/0.25 mg (Ortho TriCyclen®, Ortho-McNeil Pharmaceutical). This COC is one of the most widely prescribed COC
in the United States (9).

Study Population
Participants were deemed eligible in the study provided they met the following inclusion
criteria: (i) Pre-menopausal women, 18 to 40 years of age, (ii) lean women with BMI < 25
kg/m2 and obese women with BMI ≥ 30 kg/m2, (iii) with no COC use within past three months
of the study, (iv) expressing willingness and providing an informed consent to take part in the
study, (v) and expressing their ability to comply with the study requirements. The following were
the exclusion criteria: (i) presence of diabetes mellitus, assessed by OGTT (fasting glucose ≥
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126mg/dl or a 2 hour glucose ≥ 200mg/dl), (ii) systolic blood pressure > 160mmHg or diastolic
blood pressure > 100mmHg, (iii) presence of any pulmonary, cardiac (history of
thromboembolism, myocardial infarction, cerebrovascular accident, vascular disease or known
coagulopathy), renal, hepatic, neurological (including migraine, headaches), psychiatric,
infectious and malignant diseases, (iv) use of any hypoglycemic, gluco-corticoids, antiandrogens (e.g. spironolactone, flutamide), anti-hypertensive, lipid lowering agents that are
known to affect the glucose metabolism, (v) prolonged immobilization, or major surgery within
past six months, (vi) use of any investigational drugs within three months, (vii) pregnant or
lactating women, (viii) anemic women (hematocrit < 33%), (viii) smoker ≥ 20 cigarettes/day,
and (ix) subjects actively attempting weight loss.

Recruitment
Subjects were recruited from the student health clinics and obstetrics/gynecology centers at
Virginia Commonwealth University Medical center via poster, fliers in and around the campus.
The study was conducted at the General Clinical Research Center (GCRC).

Potential subjects were then enrolled into the study only after obtaining an informed consent.
Participants visited the GCRC for study procedures at baseline, and after three and six months of
COC administration.
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The study was approved by the Institutional Review Board (IRB) at Virginia Commonwealth
University.

Study Protocol
Recruited participants presented to the GCRC after a 12-hour overnight fast during the follicular
phase of their menstrual cycle (confirmed by a serum progesterone level of <2ng/ml). On day 1,
an OGTT with 75 gm of glucose was performed. On day 2, participants underwent the modified
frequently sampled intravenous glucose tolerance test (FSIVGTT), as described by Bergman
(61). At time 0, 300mg/kg glucose solution was administered intravenously as a bolus over 1
minute, followed by 0.03U/kg insulin infusion at 20 minutes. Blood was then drawn at -15, -5, 0,
2, 3, 4, 5, 6, 8,10, 12, 14, 16, 19, 22, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 140, 160, and
180 minutes (61;62).

Participants were then started on a COC [Ortho Tri Cyclen; containing ethinyl estradiol 35mcg
and norgestimate0.18/ 0.215/0.25 mg for a period of six months]. All participants were instructed
to take the active pill everyday for 21 days, followed by a 7 day pill free period. Participants
were also instructed to maintain their normal dietary and physical activity during the six month
period.
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Follow up
A first follow up was scheduled three months from COC use, between 5th and 7th day of the
hormone-free week, to minimize the effect by progestins on insulin kinetics. A repeated
assessment of the 2-hr OGTT was performed. A second follow up visit was scheduled six
months from baseline, between 5th and 7th day of the hormone-free week. On days 1 and 2 of the
six month follow up visit, study procedures were the same as days 1 and 2 of the baseline visit.

Methodology
All samples to be analyzed were stored at -70⁰C. Glucose was analyzed by glucose oxidase
methodology (YSI 2300 Stat Plus Glucose Analyzer, Yellow Spring Instruments (YSI), Yellow
Springs, OH), while plasma insulin was analyzed using ELISA (ALPCO Diagnostics, Salem,
NH). All samples were analyzed in duplicates.

Measurement of insulin clearance:

Plasma insulin clearance was estimated from plasma insulin measurements from FSIVGTT,
taken after exogenous administration of insulin bolus infusion, assuming a single compartment
model.

Plasma insulin concentration declines following administration of intravenous infusion of insulin
at 20 minutes. Figure 3 provides a description of how plasma insulin concentration diminishes
following intravenous insulin administration at 20 minutes. However, plasma insulin level
stabilizes and attains a steady state around 50-60 minutes.
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Figure 3: Plasma insulin-glucose concentrations, following FSIVGTT
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Steady state insulin concentration (Iss) was calculated by taking an average of the plasma insulin
levels after it stabilizes. The difference between insulin measurements (from peak insulin
concentration following insulin bolus infusion to steady state insulin concentration) is I-Iss.
Figure 4 provides a graph of I-Iss in a woman with a BMI of 24kg/m2.

Figure 4: I-Iss
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Insulin elimination constant (Ke, min-1) was determined by the negative slope of the regression
of the logarithm (I-Iss) against time (i.e. time from peak insulin concentration following insulin
infusion to steady state insulin concentration) multiplied by 2.303.

Volume of distribution (Vd, L) was calculated using the formula:
Vd= dose/C0;

Where dose was the amount of insulin infusion per kg body weight and C0 was the predicted
plasma insulin concentration (I-Iss) at 20 minutes.

Figure 5 provides a graph of both (I-Iss) and predicted (I-Iss) for the same woman as described
above.

Figure 5: (I-Iss) and predicted (I-Iss)

Insulin Concentration (mu/l)

1000.00
I-Iss
(I-Iss)pred
100.00

10.00

1.00
0

10

20

30
Time (minutes)

40

23

50

60

Finally, total insulin clearance (CLtot, L/min) was calculated using the formula (63):
CLtot= Vd * Ke

Measurement of glucose-insulin dynamics:

Glucose-insulin dynamics was calculated from modified FSIVGTT, using the Minimal Model
Identification Software (MINIMOD), version 6.02, Los Angeles, CA) (64). The aforementioned
software is a robust, accurate, reproducible and user friendly software for measuring the glucoseinsulin dynamics. Insulin sensitivity measured by this method indicates the net capacity of
insulin to promote peripheral and hepatic glucose uptake and also inhibit endogenous glucose
production. Insulin sensitivity index (Si) is calculated using the formula; Si=P3/P2 (where P3 is a
parameter describing the levels of circulating insulin in interstitial fluid and P2 is a parameter
describing the removal rate of insulin from interstitial fluid) (61;64). The minimal model also
provides estimation of glucose effectiveness (Sg), AIRg (area under the plasma insulin curve
between 0 and 10 minutes, which is a measure of first phase insulin secretion), and disposition
index (DI, which is Si * AIRg, composite measure of insulin secretion and action) (64).

Insulin and glucose incremental area-under-the-curve (AUC) upon OGTT was analyzed by the
trapezoidal rule after subtracting baseline values. Glucose-insulin values from OGTT was also
used to calculate the Matsuda insulin sensitivity index (65), using the following formula:
[10,000/ √ {(fasting plasma glucose * fasting plasma insulin) * (mean OGTT glucose
concentration * mean OGTT insulin concentration)}]. Homeostasis model assessment or HOMA
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uses a computer solved model to estimate insulin sensitivity and β cell function using the basal
steady state plasma glucose and insulin levels, given by the formula:
HOMA-Insulin Sensitivity Index=405/ [Fasting glucose (mg/dl) * Fasting insulin] (61;66).

Data Analyses
JMP 8 statistical software (SAS Institute Inc., Cary, NC) was used to perform all the analysis
using a significance level of 0.05. The primary outcome of interest was the mean change in
insulin clearance from baseline after six months of COC administration, among obese vs. lean
pre-menopausal women. Additionally, mean change in insulin clearance was also assessed
among African-American obese vs. non African-American obese pre-menopausal women. We
also looked into the overall effect of COC use on insulin clearance in all women regardless of
baseline obesity status after six months of COC administration. Relationship between changes in
insulin clearance with six months of COC use and changes in glucose-insulin indices was also
evaluated.

Normality distribution was confirmed. All continuous variables were described using mean and
standard deviation, while categorical variables were described using counts and proportion.
Baseline comparisons between lean and obese women were performed using students’ t-test in
case of equal variance, while Welch ANOVA was used if unequal variance was observed.
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Our primary research question, i.e. mean change in insulin clearance from baseline after six
months of COC use, among lean and obese pre-menopausal women was tested by repeated
measure analysis. The model consisted of insulin clearance as the outcome variable; subject ID
as a random effect, time trend, obesity status along with their interaction with time trend as fixed
effects. Similarly, mean change in insulin clearance from baseline after six months of COC use
in African-American obese and non African-American obese women was tested by repeated
measure analysis. Change in insulin clearance from baseline to six months in all women
regardless of obesity status was analyzed by paired t-test. Also, change in insulin clearance
within each of the group (lean, obese, African-American obese and non African-American
obese) was assessed by matched paired t-test.

Relationship between changes in insulin clearance and changes in glucose-insulin dynamics,
following six months of COC use was evaluated by a simple correlation test.
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4. RESULTS
Baseline Characteristics
A total of 48 pre-menopausal women provided their informed consent for the study. However,
only 27 women completed the entire course of the trial, with 4 no-shows, 4 failing to meet the
screening-eligibility criteria, 5 losses to follow up and 8 withdrawing from the study. Table 1
provides the distribution of body type and race in the analyzed (n=27) and the unanalyzed (n=21)
group.
Table 1: Distribution of body type and race in the analyzed and unanalyzed group
PARAMETER
Analyzed
(n=27)
13 (48.15%)

Lean (BMI <
25kg/m2)
Obese (BMI ≥
14 (51.85%)
2
30kg/m )
Information
Unavailable
African8 (29.63%)
Race
American
Caucasian
17 (62.96%)
Hispanic
2 (7.4%)
Asian
0
Information
Unavailable
*Indicates significant difference (p<0.05)
Body Type

GROUP
Unanalyzed
(n=21)
2 (9.5%)

P-value
<0.0001*

7 (33.33%)

0.0018*

12 (57.14%)

-

4 (19.05%)

0.0185*

8 (38.1%)
0
2 (9.52%)
7 (33.33%)

0.0002*
-

The 27 women included in the study consisted of lean (n=13) and obese (n=14) women (see
Table 2). Seven of the 14 obese women were African-Americans, while the other seven were
Caucasians (table 3).
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Table 2: Proportion of lean and obese women
Group
Lean
Obese

N
13
14

Proportion
0.481
0.518

Table 3: Proportion of African-American obese women
Group
Non African-American obese women
African-American obese women

N
7
7

Proportion
0.500
0.500

At baseline, ages of the lean and obese women in the study were similar. As predicted, obese
women had significantly higher BMI, systolic-diastolic blood pressure (BP), waist circumference
and waist-hip-ratio. Baseline demographic characteristics of the study subjects are summarized
in table 4.
Table 4: Baseline demographic characteristics of study subjects
Parameter
Lean women (n=13)
Age (yrs)
21.23 ± 2.31
2
BMI (Kg/m )
20.99 ± 1.57
Systolic BP (mmHg)
105.97 ± 9.31
Diastolic BP (mmHg) 68.28 ± 3.86
Waist Circumference 67.85 ± 8.39
(cm)
Waist-Hip-Ratio
0.705 ± 0.08
*Indicates significant difference (p<0.05)

Obese women (n=14)
22.5 ± 5.24
36.93 ± 6.75
121.71 ± 13.83
74.05 ± 8.67
99.56 ± 13.95

P value
0.4300
<0.0001 *
0.0020 *
0.0364 *
<0.0001 *

0.787 ± 0.057

0.0051 *

Mean ± standard deviation

Baseline comparison of glucose-insulin dynamics showed that obese women were less insulin
sensitive than lean women. Using the minimal model, we found that obese women had
significantly lower insulin sensitivity (difference= -3.28 units, S.E= 1.10, 95% CI= -5.56 to 28

1.00) than lean women (t= -2.97, df= 24, p= 0.0066). Significantly lower insulin sensitivity in
obese women was also demonstrated by HOMA (t= -3.245, df= 25, p= 0.0033) and Matsuda
indices (t= -2.641, df= 25, p= 0.0149). The results are summarized in table 5.

Low insulin sensitivity in obese women was compensated by hyper-secretion of insulin by the
pancreas. Obese women had significantly higher AIRg (t= 4.378, df= 18.295, p= 0.0004) in
comparison to their lean counterparts. No significant difference in insulin clearance was
observed between the two groups at baseline (table 7).
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Table 5: Baseline comparison of glucose-insulin dynamics
Parameter

Lean women (n=13) Obese women (n=14) P value

Baseline

Baseline

AIRg[mu.L-1 .min]

324.84 ± 93.69

840.38 ± 92.36

0.0004 *

Si[min-1/mu/L]

7.19 ± 0.823

3.85 ± 0.812

0.0066 *

2732.4 ± 569.47

0.6622

Incremental AUC glucose 3080.6 ± 590.97

Incremental AUC insulin

3905.9 ± 622.89

4400.84 ± 600.23

0.6151

Sg (1000.min-1)

0.037 ± 0.0058

0.028 ± 0.0058

0.4186

DI (AIRg.Si)

2161.35 ± 444.33

3126.74 ± 439.35

0.1352

ISI HOMA

1.56 ± 0.215

0.92 ± 0.207

0.0033 *

Matsuda index

11.74 ± 1.35

7.22 ± 1.3

0.0149 *

Least square mean ± standard error
*indicates significant
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Specific Aim 1: Effect of COC on insulin clearance in all women
Six months of COC use did not have any significant effect on insulin clearance when all the 27
women were analyzed together. The results are summarized in table 6.
Table 6: Effect of COC on insulin clearance in all women
Insulin clearance
(l/min)

Baseline

6 months

1.11 ± 0.078

1.2 ± 0.078

Difference (6
monthsbaseline)
0.09 ± 0.099
(95% CI= 0.115 to 0.296)

P value

0.3713

Least square mean ± standard error

Specific Aim 2: Effect of COC use on insulin clearance in lean vs. obese women
No significant difference in insulin clearance was observed after six months of COC use, based
on obesity status, as summarized in table 7. Within each of the group (i.e. lean and obese group),
no significant difference in insulin clearance was observed with six months of COC use.
Even after adjusting the insulin clearance for body weight, no significant difference [F

(1, 25)

=

0.067, p=0.7978] in insulin clearance was observed after six months of COC use between lean
and obese women.
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Table 7: Effect of COC on insulin clearance in lean vs. obese women
Parameter

Lean women
(n=13)

Obese women
(n=14)

Baseline 6
months
1.22 ±
1.27 ±
0.113
0.113

Baseline 6
months
1.01 ±
1.15 ±
0.1368
0.109
0.109

Insulin
clearance
(l/min)
0.7893
P value
(paired ttest)
Least square mean ± standard error

P value
(baseline
comparison
between
groups)

P value
(comparison of
COC effects
between
groups)

0.6703

0.2884

Specific Aim 3: Effect of COC on insulin clearance in African-American obese vs. non
African-American obese women
At baseline, there was no significant difference in insulin clearance between African-American
obese vs. non African-American obese women (Table 8). Six months of COC use resulted in no
significant effect on insulin clearance between the two groups. No significant change in insulin
clearance was also observed within each of African-American obese and non African-American
obese women group.
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Table 8: Effect of COC on insulin clearance in African-American obese vs. non AfricanAmerican obese women
Parameter

African- American Non-Africanobese women
American obese
(n=7)
women (n=7)

Baseline 6
months
0.963 ± 0.895 ±
0.129
0.129

Insulin
clearance
(l/min)
0.2816
P value
(paired ttest)
Least square mean ± standard error

P value
(baseline
comparison
between
groups)

Baseline 6
months
1.07 ±
1.4 ±
0.5184
0.129
0.129

P value
(comparison of
COC effects
between
groups)

0.0957

0.1706

Specific Aim 4: Relationship between changes in insulin clearance and changes in glucoseinsulin dynamics with COC use (taking all the women into consideration)
Changes in insulin clearance with six months of COC was found to be significantly related to
changes in AIRg, insulin sensitivity as measured by minimal model, incremental AUC glucose
and glucose effectiveness (Table 9). Changes in insulin clearance was positively related with
changes in insulin sensitivity (figure 6) and negatively related with changes in AIRg (figure 7).
However, no significant relationship was observed between changes in insulin clearance and
changes in incremental AUC glucose, disposition index, and insulin sensitivity measured by
HOMA and Matsuda index.
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Table 9: Relationship between changes in insulin clearance and changes in glucose-insulin
dynamics after six months of COC use

Parameter
AIRg
[mu.L-1 .min]
Si
[min-1/mu/L]

Insulin clearance (l/min)
Correlation (r)
P value
-0.432
0.0034 *
0.385

0.0099 *

Incremental AUC glucose

0.4257

0.0040 *

Incremental AUC insulin

0.1298

0.401

Sg (1000.min-1)

0.484

0.0009 *

DI (AIRg.Si)

-0.029

0.8503

ISI HOMA

0.225

0.1413

Matsuda index

0.120

0.4363

*indicates significant

Figure 6: Scatter plot showing the relationship between changes in insulin clearance and
changes in insulin sensitivity following six months of COC use

34

Figure 7: Scatter plot showing the relationship between changes in insulin clearance and
changes in AIRg following six months of COC use
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5. DISCUSSION
Obesity has been correlated with hyperinsulinemia, and this effect is attributed to both
compensatory hyper-secretion of insulin by the pancreas secondary to insulin resistance and
decreased insulin clearance. In a previous study, we have reported the effects of COC on insulin
sensitivity in lean and obese women (14). Six months of COC use showed divergent effects on
insulin sensitivity in lean vs. obese women, as measured by the minimal model (p=0.0494).
These effects were also demonstrated by other measures of insulin sensitivity, such as the
Matsuda index (p=0.0227) and ISI HOMA (p=0.0128). In the above mentioned study, following
six months of COC administration, insulin sensitivity worsened in obese women and improved in
lean women. No significant difference was observed between lean and obese women in changes
in AIRg during six months of COC use (14). Considering the worsening of insulin sensitivity and
no change in AIRg in obese women, we were interested to see if insulin clearance had a role to
play in contributing to hyperinsulinemia. Hence, in this study, we set out to examine whether a
commonly used COC affect insulin clearance, and whether effects on insulin clearance is
different between lean and obese women.

Insulin clearance involves both first-pass hepatic elimination (30) and peripheral insulin uptake,
internalization and degradation. At physiological concentration (10-9 M), insulin uptake is a
receptor mediated process, while at non-physiological concentration, non-receptor mediated
processes predominates (67). Liver contributes to about 50-70% of insulin degradation (29),
while kidney is the main site for insulin clearance from the systemic circulation (67). Other sites
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of insulin uptake and degradation comprises of pancreas, adrenal gland, testis, spleen, ovary,
lung, heart, muscles, brain and fat.

In the present study, there was no differential effect on insulin clearance in lean vs. obese
women, after six months of COC administration. One of the possible reasons for this could be
because of our choice of progestin. We based our choice of COC (ethinyl estradiol 35 mcg and
norgestimate 0.18/0.215/0.25 mg) used in the study on agents that are most commonly used.
Although we reported a differential effect of norgestimate-containing COC on insulin sensitivity
in lean vs. obese women in a previous study (14), other studies have shown a metabolic neutral
effect. Norgestimate, a 3rd generation gonane progestin is known to have minimal metabolic
effects (54;68-72). It also has a low androgenic profile (70). Use of a norgestimate-containing
oral contraceptive for a period of 2 years among healthy women was not associated with
clinically significant changes in fasting plasma glucose or insulin levels (54). Only 2% of the
women on norgestimate-containing COC developed abnormal fasting glucose levels after six
months of use, while 35% lowered their initial abnormal glucose levels into the normal range
after six months of use (71). Additionally, norgestimate containing COC have also shown
favorable effect on lipid profile, including elevation of HDL, reduction of LDL and improved
HDL/LDL ratio (69;71). These results suggest that norgestimate containing COC show minimal
effect on glucose-insulin dynamics.

No differential effect on insulin clearance was also observed between African-American obese
(n=7) vs. non African-American obese (n=7) women after six months of COC use. It is
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interesting to note that even in a small sample size of 7 in each group; the effect reached a
significance level of 0.0957, suggesting that it may be worthwhile to repeat this study in a larger
cohort.

Changes in insulin clearance with six months of COC use was found to have a negative
relationship with changes in AIRg and a positive relationship with changes in insulin sensitivity,
as measured by the minimal model. Causations cannot be established with this study. Limited
information exists regarding the association between hyperinsulinemia and decreased insulin
clearance. It is also possible that with a higher AIRg, pancreatic insulin secretion may continue
while insulin is being cleared, resulting in a net reduced insulin clearance.

In the present study, total insulin clearance was quantified from insulin concentration obtained
during FSIVGTT test. It is reported that the plasma insulin concentration declines following
intravenous insulin infusion, with at least two exponential decay (63). Hence, steady state
insulin concentration was used to determine the total insulin clearance. Total clearance was
obtained by the product of insulin elimination constant and volume of distribution (Vd=
Dose/C0), with dose of insulin infusion adjusted to body weight of each individual. However,
some methodological inadequacies are present in this study. Insulin degradation is described as
linear first order kinetics, considering the narrow concentration intervals. This could be a
possible limitation of the study as some amount of non-linearity has been demonstrated owing to
saturable processes (73). The given study does not provide a measure of endogenous insulin
production and its subsequent clearance. In the case of exogenous insulin infusion, endogenous
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insulin secretion is suppressed by somatostatin (29). Under this condition, insulin clearance by
the liver and peripheral tissue occurs in parallel. Metabolic clearance (MCR) of endogenous and
exogenous insulin is related by the following formula: (29)

MCRendogenous= MCRexogenous / (1-Eh);
Where Eh is the hepatic extraction ratio

Besides methodological constraints, any discrepancy in the insulin clearance data from the
proposed hypothesis could also be due to the small number of women studied in each of the
groups. Lack of significant differences could also be attributed to lack of power, owing to small
sample size. Also, the study was conducted for a period of six months. Considering that
contraception methods are used over a long period of time for their desired purpose, it may be
more meaningful to study changes over a period longer than six months. It has been
hypothesized that an inverse relationship exist between dietary carbohydrate to fat ratio and
insulin clearance (36). Hence, type of diet could have an effect on insulin clearance, which was
not controlled for in this study. It will be impractical to control study participants’ diet for the
duration of the study.

The purported study is significant as it provided information on total insulin clearance in lean vs.
obese women after six months of COC use, and addressed another potential mechanism of
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hyperinsulinemia in COC users. The study also provided insights on the effect of insulin
clearance among African-American obese vs. non African-American obese women.

The choice of COC formulation is important as excessive estrogenic activity is known to cause
untoward thromboembolic effects, while progestins are known to have a deleterious effect on
carbohydrate metabolism. Overall, the pilot study showed no differential effect on insulin
clearance in lean vs. obese women after six months of COC use [Ortho Tri Cyclen; containing
ethinyl estradiol 35mcg and norgestimate0.18/ 0.215/0.25 mg]. The study may suggest that
norgestimate has minimal effect on insulin clearance, in contrast to previous studies using other
progestins.

Given that insulin clearance does not seem to be affected by the COC used in this study, future
work on hyperinsulinemia as a result of contemporary COC use should focus on mechanisms for
increased pancreatic insulin secretion and/or insulin resistance, and the effects of exogenous
hormones on these processes.
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